Budget 2026 Drives ₹10,000 Crore ‘Biopharma Shakti’ Push; Biocon and Sector Stocks React

In Union Budget 2026, Finance Minister Nirmala Sitharaman unveiled the “Biopharma Shakti” programme with a ₹10,000 crore outlay over the next five years to build a robust domestic biologics and biosimilars ecosystem and position India as a global biopharma manufacturing hub; this strategic capital commitment includes setting up three new biopharma-focused NIPER institutes, upgrading seven existing ones, establishing a network of 1,000+ accredited clinical trial sites, and strengthening regulatory processes to meet global standards moves designed to accelerate research, innovation and production capabilities. Following this announcement,

share price climbed about 2–3 per cent, rising near ₹375 per share during early trade, reflecting positive market sentiment, while other pharma names also saw notable gains as investors priced in improved long-term growth prospects for complex biologics and biosimilars driven by policy support. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.